---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-26-000009"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:40:43.550206+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances

## Summary
- Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.
- Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.
- DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.
- ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.
- Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026.

## SEC filing metadata
- accession: 0001689375-26-000009
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/0001689375-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937526000009/trda-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-26-000009
- JSON: https://secwatch.observer/filing/0001689375-26-000009.json
- Plain text: https://secwatch.observer/filing/0001689375-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.